MarketPeel
Insider Trading Intelligence
NP

Nick Pizzie

AXSM
CHIEF FINANCIAL OFFICER · AXSOME THERAPEUTICS, INC. · CIK 0001742143
FILING MIX · LIFETIME77%/23%
BUYS
27
SELLS
8
TOTAL VALUE
$12.49M
COMPANIES
1
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
75,867
AVG SELL PX
$162.43
TRADE KIND
SHOWING 35 / 35
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
8 backtested trades · 8 horizons · 5 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Nick Pizzie, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d8+87.50%+4.48%+0.39%+4.09%+6.63%
14d8+50.00%-4.34%-1.92%-2.42%-3.29%
30d8+37.50%-2.42%-1.85%-0.56%+0.94%
60d8+37.50%-14.92%-2.81%-12.10%-12.72%
90d8+50.00%-10.55%-1.39%-9.16%-6.59%
180d8(1 pending)+42.86%-6.87%-2.28%-4.59%+6.85%
1y8(1 pending)+57.14%+42.62%+1.32%+41.30%+72.24%
2y8(3 pending)+80.00%+44.16%+4.88%+39.27%+69.29%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AXSM · 75,867 shares · as of Jun 9, 2026
026,25052,50078,750105,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 27 buys / 8 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
33,000$240.09$7.92M42,867Jun 9, 2026Jun 9, 2026View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
Chief Financial Officer
33,00072,000Jun 9, 2026Jun 9, 2026View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
33,000$3.50$115.5K75,867Jun 9, 2026Jun 9, 2026View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,1888,188Apr 21, 2026Apr 23, 2026View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
18,57018,570Feb 26, 2026Feb 27, 2026View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
12,000$3.50$42.0K54,588Jan 22, 2026Jan 23, 2026View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,000$187.92$2.26M42,588Jan 22, 2026Jan 23, 2026View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
Chief Financial Officer
12,000105,000Jan 22, 2026Jan 23, 2026View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,4239,423Feb 24, 2025Feb 25, 2025View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,4239,423Feb 21, 2025Feb 25, 2025View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,5169,516Feb 21, 2025Feb 25, 2025View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,000$131.07$393.2K42,187Feb 14, 2025Feb 14, 2025View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
3,000$3.50$10.5K45,187Feb 14, 2025Feb 14, 2025View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,000$3.50$10.5K0Feb 14, 2025Feb 14, 2025View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,000$129.86$1.56M42,187Feb 13, 2025Feb 14, 2025View →
AXSM
AXSOME THERAPEUTICS, INC.
SALE
Chief Financial Officer
12,000$3.50$42.0K0Feb 13, 2025Feb 14, 2025View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
12,000$3.50$42.0K54,187Feb 13, 2025Feb 14, 2025View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,77415,774Feb 27, 2024Feb 29, 2024View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
28,72228,722Feb 27, 2024Feb 29, 2024View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,55420,554Mar 2, 2023Mar 6, 2023View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
36,24636,246Mar 2, 2023Mar 6, 2023View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
41,17641,176Mar 4, 2022Mar 8, 2022View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
77,87277,872Mar 4, 2022Mar 8, 2022View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
CHIEF FINANCIAL OFFICER
142$35.20$5.0K142Nov 18, 2021Nov 22, 2021View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
CHIEF FINANCIAL OFFICER
141$35.43$5.0K201Nov 18, 2021Nov 22, 2021View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
CHIEF FINANCIAL OFFICER
145$34.30$5.0K145Nov 18, 2021Nov 22, 2021View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
CHIEF FINANCIAL OFFICER
527$35.50$18.7K41,789Nov 18, 2021Nov 22, 2021View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
36,08636,086Nov 12, 2021Nov 15, 2021View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,20819,208Mar 5, 2021Mar 9, 2021View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
36,08636,086Mar 5, 2021Mar 9, 2021View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
777$76.64$59.5K41,217Jun 29, 2020Jun 30, 2020View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
48,23748,237Mar 17, 2020Dec 23, 2020View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,76714,767Mar 17, 2020Dec 23, 2020View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,88060,880Mar 17, 2020Mar 19, 2020View →
AXSM
AXSOME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
18,64518,645Mar 17, 2020Mar 19, 2020View →
Other insiders · AXSM
Loading peer insiders…
About this filer
CIK 0001742143
ROLE
CHIEF FINANCIAL OFFICER
PRIMARY
AXSM
COMPANIES
1
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001742143DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback